2.3万 件 ・ 関連度順
概要と使いどころ
プリミティブ型をドメイン固有型でラップすべきか否かの判断を支援する。 Primitive Obsession（プリミティブ型の過剰使用）と Value Object Obsession（過剰なラップ）の 両極端を避け、投資対効果に基づく合理的な判断基準を提供する。 Value Objectの定義が文脈（PofEAA/DDD/一般）で異なることによる用語混乱の防止も含む。 コードレビュー、新規実装、設計議論時にプリミティブ型のラップ判断が必要な場合に使用。 対象言語: 言語非依存（Rust, TypeScript, Java, Kotlin, Scala, Go, Python等すべて）。 トリガー：「この値をラップすべきか」「プリミティブ型のままでいいか」 「Value Objectにすべきか」「型を作りすぎでは」「Primitive Obsession」 「ラップしすぎ」「型が多すぎる」「Stringのままでいいか」 といったプリミティブ型ラップ判断関連リクエストで起動。
Claim value trending and replacement cost tracking. Triggers: "claim value trending", "replacement cost tracking", "vehicle depreciation for claims", "residual value for insurance", "how fast is the insured vehicle losing value", "pre-loss value trajectory", "depreciation rate for settlement", "value retention for claims", "depreciation curve for total loss", "diminished value over time", "claim reserve adjustment", "portfolio depreciation exposure", "fleet depreciation risk", tracking vehicle depreciation for insurance claims valuation, replacement cost estimation, settlement trending, or reserve adequacy assessment.
日本語の概要は準備中です。原文の説明を表示しています。
Manage change control for validated computerized systems. Covers change request triage (emergency, standard, minor), impact assessment on validated state, revalidation scope determination, approval workflows, implementation tracking, and post-change verification. Use when a validated system requires a software upgrade, patch, or configuration change; when infrastructure changes affect validated systems; when a CAPA requires system modification; or when emergency changes need expedited approval and retrospective documentation.
日本語の概要は準備中です。原文の説明を表示しています。
Genereert uit een (semi-)gevalideerd regelrecht-corpus een geloofwaardige service-PoC (burger- + behandelaar-portaal, of een headless beslis-service) en zet die in als validatie-instrument met uitvoeringsexperts — om tastbaar te maken wat nodig is om een wet rechtvaardig in de praktijk te brengen, gezien vanuit de betrokkene. Gebruik dit als workshop-fase ná de logica-/scenariovalidatie (audit-products) om de dienstverlening-kant te valideren: welke service impliceert de wet, waar zit menselijk oordeel, welke last ligt bij de burger, welke termijnen, waar is de wet hard of onduidelijk. Dossier-agnostisch; de regelrecht-methode (hooks, legal_character, untranslatables, source/implements, type_spec, receipts) is de vaste taal. Voor de logica-/scenariovalidatie zelf: zie de zusterskill regelrecht-audit-products.
日本語の概要は準備中です。原文の説明を表示しています。
Query gnomAD (Genome Aggregation Database) for population allele frequencies, gene constraint scores, and variant annotations to interpret ENCODE regulatory variants. Use when the user needs allele frequencies for variants in ENCODE regulatory elements, wants to assess gene constraint (pLI, LOEUF) for ENCODE target genes, needs population-specific frequencies for GWAS variants overlapping cCREs, wants to filter variants by rarity before functional annotation, or is interpreting ENCODE CRISPR/MPRA results in the context of population genetics. Also use when the user mentions gnomAD, allele frequency, pLI, LOEUF, constraint, rare variants, population frequency, ExAC, or variant filtering.
日本語の概要は準備中です。原文の説明を表示しています。
Measures and improves the quality of AI models and agents on Google Cloud using the Eval Quality Flywheel methodology. Use when evaluating an agent or model, building an eval dataset, picking or writing evaluation metrics, analyzing failures, comparing results before and after a fix, or when guidance is needed on Agent Platform eval methodology — including dataset schema, LLM-as-judge scoring, and common failure causes. For fine-tuning, use agent-platform-tuning. For general production deployment, use agent-platform-deploy.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2/PE3/PE3b/PEmax variants, MOSAIC in situ saturation mutagenesis, the PRIME pooled-screen methodology (Ren 2023; ~3,699 ClinVar variant screens), chromatin context as a major locus-level determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.
日本語の概要は準備中です。原文の説明を表示しています。
Detects somatic mutations in circulating tumor DNA, treating low-VAF detection as a signal-versus-noise problem set by error suppression and molecules sampled, not by the choice of caller. Distinguishes de novo CALLING (scanning a panel for unknown variants, bounded by per-locus error and multiple testing) from tumor-informed DETECTION (tracking a pre-specified variant set, where panel integration reaches single-ppm). Covers VarDict and Mutect2 for de novo calling, UMI-aware callers, and a pysam-based known-variant VAF tracker, with matched-WBC subtraction as the mandatory defense against clonal hematopoiesis (the dominant false positive). Use when calling or tracking tumor mutations from plasma cfDNA, setting a VAF threshold, or deciding whether a low-VAF call is tumor versus CHIP.
日本語の概要は準備中です。原文の説明を表示しています。
Treats a ctDNA assay as a molecule-counting experiment at the Poisson edge and builds its analytical-validation case the measurement-science way. Covers the genome-equivalent currency (~330 haploid copies/ng), the lambda = input_GE x VAF sampling ceiling (lambda>=3 for ~95% detection), the error-suppression ladder (raw NGS ~1e-3 -> single-strand UMI ~1e-4/1e-5 -> duplex <1e-7), the CLSI EP17 LoB/LoD/LoD95/LoQ framework, the per-locus-vs-panel-integrated LoD distinction that lets bespoke MRD reach ppm, contrived/SEQC2 reference standards, and honest LoD reporting conditioned on input mass + consensus depth + replicate detection rate. Use when stating or trusting a sensitivity claim, designing a dilution-series validation, deciding how many genome equivalents are needed at a target VAF, choosing a single-locus vs panel-integrated LoD, or auditing a "detects 0.1% VAF" claim.
日本語の概要は準備中です。原文の説明を表示しています。
Quando o usuário quer criar páginas de comparação com concorrentes ou alternativas para SEO e ativação de vendas. Use também quando o usuário menciona 'página de alternativas', 'página vs', 'comparação com concorrentes', 'página de comparação', '[Produto] vs [Produto]', '[Produto] alternativa', ou 'landing pages competitivas'. Cobre quatro formatos: alternativa singular, alternativas plurais, você vs concorrente, e concorrente vs concorrente. Enfatiza pesquisa profunda, arquitetura de conteúdo modular e tipos de seção variados além de tabelas de recursos.
日本語の概要は準備中です。原文の説明を表示しています。
Azure Batch SDK for Java. Run large-scale parallel and HPC batch jobs with pools, jobs, tasks, and compute nodes. Triggers: "BatchClient java", "azure batch java", "batch pool java", "batch job java", "HPC java", "parallel computing java".
日本語の概要は準備中です。原文の説明を表示しています。
Azure App Configuration SDK for Java. Centralized application configuration management with key-value settings, feature flags, and snapshots. Triggers: "ConfigurationClient java", "app configuration java", "feature flag java", "configuration setting java", "azure config java".
日本語の概要は準備中です。原文の説明を表示しています。
Create an Estuary derivation that joins two or more collections on a shared key, merging their fields into a single enriched collection. Use for data enrichment, denormalisation, building wide tables for BI, and real-time CDC joins. Derivations add complexity and cost — confirm the user wants a derivation before reaching for this (a destination-side SQL join or BI tool view is often simpler). Use when user says "join-collections derivation", "derivation to join two collections", "transformation to enrich with customer data", "derive a wide table", "lookup-join derivation", or "build a join derivation".
日本語の概要は準備中です。原文の説明を表示しています。
Use when working on any Java or JVM project: plain Java, libraries, CLI tools, Maven/Gradle builds, Spring Boot, Jakarta EE, MyBatis/MyBatis-Plus, JPA/Hibernate, Lombok, Java tests, Java code review, API design, exception handling, security review, refactoring, dependencies, Java version upgrades, javax/jakarta migrations, or JVM runtime troubleshooting such as GC, OOM, thread dumps, deadlocks, high CPU, and performance issues.
日本語の概要は準備中です。原文の説明を表示しています。
Builds and validates predictive time-to-event models on clinical and omics data with penalized Cox, random survival forests, gradient-boosted and deep survival models, and prediction-grade evaluation (Uno's C, time-dependent AUC, integrated Brier, calibration, competing risks). Use when building an individualized risk predictor or prognostic omics signature, choosing a survival model, or evaluating one beyond the C-index. For Kaplan-Meier, log-rank, and classical Cox hazard-ratio inference in a trial see clinical-biostatistics/survival-analysis.
日本語の概要は準備中です。原文の説明を表示しています。
Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
日本語の概要は準備中です。原文の説明を表示しています。
Figma REST API / Plugin API / Widget API / Code Connect / MCP Server リファレンス。 OAuth / Personal Access Token / Plan Access Token 認証、files, variables, webhooks, Dev Mode, Dev Resources, SCIM, activity-logs, library-analytics エンドポイント。 figma グローバルオブジェクト、node types (FrameNode, TextNode, ComponentNode 等)、 data types、figma.variables、figma.codegen、figma.ui。 useSyncedState, useSyncedMap, usePropertyMenu, AutoLayout, register。 Code Connect CLI / UI / React / SwiftUI / Compose / HTML / Storybook / custom parsers。 Figma MCP Server ツール・プロンプト・Code to Canvas・Write to Canvas。
Swift Standard Library・Concurrency・プロトコル/ジェネリクス・Observation リファレンス。 async/await、actor、Sendable、Task、TaskGroup、AsyncSequence、AsyncStream、 Equatable、Hashable、Comparable、Codable、Identifiable、Optional、Result、 generics、some/any opaque types、Observable、@Observable、ObservationRegistrar。
Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 (Mathis 2023/2024) for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2 / PE3 / PE3b / PEmax / PEAR variants, MOSAIC in situ saturation mutagenesis (Hsu JY et al 2024 bioRxiv), the PRIME pooled-screen methodology (Erwood/Doman 2023 Nat Biotechnol 41:885; ~3,699 ClinVar variant screens), chromatin context as a primary determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.
日本語の概要は準備中です。原文の説明を表示しています。
Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
日本語の概要は準備中です。原文の説明を表示しています。
Use when publishing, unpublishing, replicating, or activating/deactivating content in AEM 6.5 LTS. Covers Quick Publish, Manage Publication, tree activation, bulk content activation, package replication, workflow-based approval, scheduled activation/deactivation (on/off time), dispatcher flush, and the programmatic Replication Java API for AEM publish instances.
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrator for the eval-output skill suite — evaluate LLM and agent outputs for quality, accuracy, helpfulness, and safety using structured rubrics and LLM-as-judge techniques. Load when the user says "evaluate this output", "score this response", "run an eval", "LLM as judge", "evaluate agent output", "how good is this response", "rate this answer", "eval this", or provides an LLM output that should be assessed for quality. Single entry point for all output evaluation workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and analyzes pooled prime-editor (PE) screens for installing precise genetic variants without bystander confounding. Covers pegRNA design with PRIDICT and PRIDICT2 (Mathis 2023/2024) for predicting per-pegRNA editing efficiency, pegRNA architecture (spacer + scaffold + PBS + RTT), PE2 / PE3 / PE3b / PEmax / PEAR variants, MOSAIC in situ saturation mutagenesis (Hsu JY et al 2024 bioRxiv), the PRIME pooled-screen methodology (Erwood/Doman 2023 Nat Biotechnol 41:885; ~3,699 ClinVar variant screens), chromatin context as a primary determinant of PE efficiency, scaffold-incorporation and indel byproduct quantification with CRISPResso2, and the cross-modal validation strategy of PE + base-editor screens for variant function. Use when designing a pegRNA library for variant installation, choosing between BE and PE for a specific edit, predicting pegRNA efficiency before library synthesis, analyzing PE screen output, distinguishing intended-edit from scaffold-incorporation, or scaling PE screens to thousands of variants.
日本語の概要は準備中です。原文の説明を表示しています。
Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
日本語の概要は準備中です。原文の説明を表示しています。